-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to French media reports, a large-scale study involving about 22 million people showed that vaccination of the new crown vaccine can reduce the risk of hospitalization and death by 90% for people over 50 years old, and the vaccine is also effective against Delta variants
The scientific research team "Epi-Phare" (Epi-Phare), composed of the French Medical Insurance Agency and the French National Drug Safety Administration, released the latest research results
The head of Epidemiology Beacon and epidemiologist Mahmoud Zrik said: “The risk of vaccinated people being hospitalized or dying from new coronary pneumonia is 1/9 of those of unvaccinated people
Since the Delta variant is currently the most popular variant of the new coronavirus, researchers have made a special assessment of the vaccine effect during the widespread spread of the Delta variant
Research leader Zrik pointed out that although preliminary information is provided on the protective effect of the vaccine on the Delta variant, "the research phase is too short to assess the true effect of the vaccine on this variant strain
The new crown vaccines involved in the research include Pfizer, Modena, and Oxford/AstraZeneca vaccines.